Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Foster New Partnerships with its Expanding DehydraTECH(TM) Licensing Opportunities

  • Lexaria’s patented DehydraTECH(TM) technology improves how APIs enter the bloodstream through the promotion of healthier oral ingestion methods while also increasing the effectiveness of fat-soluble active molecules
  • As a disruptive technology, its impact has been felt by other players in its space, leading Lexaria to open its doors to partnering with industry experts and implementing the technology across many fields, including licensing the technology to Fortune 100 companies
  • Lexaria will continue to make its technology accessible, improving the lives of people around the world

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has, since 2016, repeatedly demonstrated the potential of its patented technology, DehydraTECH(TM). The technology improves how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods while increasing the effectiveness of fat-soluble active molecules. With the help of this technology, Lexaria has explored potential treatment options for a variety of conditions, including hypertension, epilepsy, and even nicotine replacement.

The overall potential of DehydraTECH to be used to improve existing products or create new ones has seen its application in a growing range of consumer product formats, from topical applications to oral suspensions, registered drugs, nutraceuticals, consumer packaged goods, capsules, pills, and tablets. Furthermore, as a disruptive patented technology, its impact has been felt by other players in its space, leading to Lexaria opening its doors to partnering with Fortune 100 companies to implement the technology across many fields (https://cnw.fm/niPD8).

Lexaria, through its licensing program, is making its technology accessible to more people, potentially improving the lives of hundreds of thousands, if not millions of people around the world. With the company having set its eyes on the commercial execution of its DehydraTECH technology for the new year, its licensing program will play a key role in achieving this end. Its management remains optimistic that, as its licensing program grows, more companies will come on board, bringing its technology closer to the masses.

Currently, Lexaria engages in strategic partnerships with third-party companies interested in exploring formulation opportunities with their specific APIs of interest. It also out-licenses its technology in exchange for up-front fees, milestone payments, and/or royalty payments, while offering dietary supplement GMP-grade intermediate formulations to corporate clients on a toll-processing basis.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition Cannexpo Marigold PR MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo Tether BudTender Tether BudTender Appreciation Week

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722